A new look at the respiratory stimulant doxapram.
Article Details
- CitationCopy to clipboard
Yost CS
A new look at the respiratory stimulant doxapram.
CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49.
- PubMed ID
- 17227289 [ View in PubMed]
- Abstract
A number of life-threatening clinical disorders may be amenable to treatment with a drug that can stimulate respiratory drive. These include acute respiratory failure secondary to chronic obstructive pulmonary disease, post-anesthetic respiratory depression, and apnea of prematurity. Doxapram has been available for over forty years for the treatment of these conditions and it has a low side effect profile compared to other available agents. Generally though, the use of doxapram has been limited to these clinical niches involving patients in the intensive care, post-anesthesia care and neonatal intensive care units. Recent basic science studies have made considerable progress in understanding the molecular mechanism of doxapram's respiratory stimulant action. Although it is unlikely that doxapram will undergo a clinical renaissance based on this new understanding, it represents a significant advance in our knowledge of the control of breathing.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Doxapram Potassium channel subfamily K member 3 Protein Humans YesInhibitorDetails Doxapram Potassium channel subfamily K member 9 Protein Humans YesInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareDoxapramLinezolid Linezolid may increase the hypertensive activities of Doxapram. DoxapramFurazolidone Furazolidone may increase the hypertensive activities of Doxapram. DoxapramProcaine Procaine may increase the hypertensive activities of Doxapram. DoxapramTranylcypromine Tranylcypromine may increase the hypertensive activities of Doxapram. DoxapramPhenelzine Phenelzine may increase the hypertensive activities of Doxapram.